Nazım Can Demircan

Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?

Osman Köstek, Muhammet Bekir Hacıoğlu, Abdullah Sakin et al. · Cancer Chemotherapy and Pharmacology · 2018 · 33 citations

Oncology, Colorectal Cancer, Metastatic Colorectal Cancer +7

Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?

Özkan Alan, Tuğba Akın Telli, Bilge Aktaş et al. · World Journal of Surgical Oncology · 2020 · 31 citations · Full text

Surgical Oncology, Breast Oncology, Cancer Management +18

Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib

Ali Gökyer, Ahmet Küçükarda, Osman Köstek et al. · Clinical & Translational Oncology · 2019 · 22 citations

Oncology, Gastrointestinal Oncology, Medicine +9

Dynamic changes in systemic immune‐inflammation index predict pathological tumor response and overall survival in patients with gastric or gastroesophageal junction cancer receiving neoadjuvant chemotherapy

Nazım Can Demircan, Muhammed Mustafa Atçı, Metin Demir et al. · Asia-Pacific Journal of Clinical Oncology · 2022 · 18 citations

Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib

Nazım Can Demircan, Özkan Alan, Tuğba Başoğlu et al. · Journal of Oncology Pharmacy Practice · 2019 · 14 citations